AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03282435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cells with PD-1 blocking
Description: CIK cellular therapy with PD-1 blocking
Study NCT03282435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard lung cancer treament
Description: standard non-small cell lung cancer treatment: surgery, chemotherapy
Study NCT03282435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard lung cancer treament
Description: standard non-small cell lung cancer treatment: surgery, chemotherapy
Study NCT03282435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CIK cells without PD-1 blocking
Description: CIK cellular therapy without PD-1 blocking
Study NCT03548376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
Study NCT01306253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1
Study NCT00306631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
Study NCT02940990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
Description: two-drug regimen
Study NCT03152552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 was supplied in different doses as tablets taken orally.
Study NCT03152552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as tablets and capsules taken orally.
Study NCT03152552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin was supplied as capsules taken orally.
Study NCT03421691 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: excel V Laser
Description: excel V Laser Genesis procedure utilizing 1064 nm laser
Study NCT04488536 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: Frailty assessment
Study NCT03389802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients
Description: APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first.
Study NCT03389802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M treatment for newly diagnosed DIPG patients
Description: The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first.
Study NCT03052179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Poly-biotic
Description: Before-after treatment
Study NCT03052179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Poly-biotic
Description: Before-after treatment
Study NCT03662945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Team intervention
Description: Person-centred intervention based on Comprehensive Geriatric Assessment
Study NCT01383538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX, IPI-926
Description: Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle.
Study NCT00733317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg/ml budesonide nebules
Description: Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
Study NCT00733317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Children will receive 2 ml of saline every 20 minutes for 3 times
Study NCT02759159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: true acupuncture
Description: acupuncture at the four-gateacupoints, three times per week and last for 6 months
Study NCT02759159 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months
Study NCT03609827 — intervention group
Intervention type: DRUG
Intervention: Melphalan
Study NCT02692300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG-Guided Group
Description: Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
Study NCT02495753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Cleansing
Description: The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
Study NCT02495753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Cleansing
Description: The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
Study NCT02495753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Cleansing
Description: The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
Study NCT01710072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT06470529 — intervention group
Intervention type: DEVICE
Intervention: drug eluting stents
Description: different types of drug eluting stents
Study NCT04100772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i
Study NCT04100772 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL,Intramuscular other name:Prevnar
Study NCT03355079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven® E
Description: In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
Study NCT01494051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
Study NCT01494051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet counseling
Description: Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 20mg
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 80mg
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl Placebo
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone Methyl Placebo
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bardoxolone Methyl Placebo
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Oral
Study NCT01689116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Oral
Study NCT02623673 — intervention group
Intervention type: DRUG
Intervention: simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.
Study NCT01664078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular AAA repair with InCraft®
Study NCT03743038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101 vehicle
Description: FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
Study NCT03743038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydro-alcohol solution
Description: Hydro-alcohol solution based vehicle (Test Article B)
Study NCT04215029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive exercise plan
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive printed exercise materials
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive physical activity and healthy eating information/materials
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Complete nutrition counseling sessions
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04215029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04215029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching calls
Study NCT02302079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: oral capsule
Study NCT02302079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal (IVT) injection
Study NCT02302079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: intravitreal (IVT) injection
Study NCT02302079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT02302079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham intravitreal (IVT) injection
Description: intravitreal (IVT) injection
Study NCT03286023 — intervention group
Intervention type: RADIATION
Intervention: stereotactic radiotherapy
Description: stereotactic radiotherapy for brain metastases
Study NCT02500225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: 0.2 mg/kg etomidate
Study NCT02500225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 8% Sevoflurane
Study NCT02167022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and occupational therapy
Description: The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
Study NCT01517698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to RO4917523 orally once a day for 12 weeks
Study NCT01517698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 0.5 mg
Description: 0.5 mg orally once a day for 12 weeks
Study NCT01517698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 1.5 mg
Description: 1.5 mg orally once a day for 12 weeks
Study NCT03956498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy
Description: * Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24.
Study NCT03822923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
Study NCT03822923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional treatment
Study NCT03376321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Description: Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Study NCT03376321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Study NCT03376321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
Study NCT03376321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
Study NCT03277313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Study NCT01700608 — intervention group
Intervention type: DRUG
Intervention: plerixafor
Description: plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
Study NCT02030977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Study NCT02030977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03340051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Future Thinking (EFT)
Description: EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
Study NCT03340051 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Description: ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
Study NCT01704092 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Study NCT01965834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
Study NCT02863640 — intervention group
Intervention type: DEVICE
Intervention: Color retinography
Study NCT02863640 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography
Study NCT02863640 — intervention group
Intervention type: DEVICE
Intervention: Fundus autofluorescence imaging
Study NCT02342067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
Study NCT02342067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
Study NCT00423124 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HSV-TK
Description: Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
Study NCT02276300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Treatment of mild Endoxan application three days before Her2 vaccination
Study NCT02276300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim is part of Her2 vaccination
Study NCT02276300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2-Peptid-Vakzine
Description: Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
Study NCT02276300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod is part of Her2 vaccination
Study NCT03068403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
Description: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
Study NCT03674177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 1
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
Study NCT03674177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 2
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
Study NCT03674177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 3
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
Study NCT03674177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm